Determination of ω-6 and ω-3 PUFA metabolites in human urine samples using UPLC/MS/MS
详细信息 查看全文
- 作者：Ai Sasaki ; Hayato Fukuda ; Narumi Shiida…
- 关键词：Eicosanoids ; Polyunsaturated fatty acids ; Specialized pro ; resolving mediators ; UPLC/MS/MS ; Urine
- 刊名：Analytical and Bioanalytical Chemistry
- 出版年：2015
- 出版时间：February 2015
- 年：2015
- 卷：407
- 期：6
- 页码：1625-1639
- 全文大小：449 KB
- 参考文献：1. Buczynski MW, Dumlao DS, Dennis EA (2009) Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res 50:1015-038 CrossRef
2. Hishinuma T, Koseki Y, Murai Y, Yamazaki T, Suzuki K, Mizugaki M (1999) Urinary thromboxane A2/prostacyclin balance reflects the pathological state of a diabetic. Prostaglandins Other Lipid Mediat 58:263-71 CrossRef
3. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, Johnson DH, Morrow JD (2004) Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 334:266-75 CrossRef
4. Cai Q, Gao YT, Chow WH, Shu XO, Yang G, Ji BT, Wen W, Rothman N, Li HL, Morrow JD, Zheng W (2006) Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol 24:5010-016 CrossRef
5. Dong LM, Shu XO, Gao YT, Milne G, Ji BT, Yang G, Li HL, Rothman N, Zheng W, Chow WH, Abnet CC (2009) Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women’s health study. Cancer Epidemiol Biomarkers Prev 18:3075-078 CrossRef
6. Ono E, Taniguchi M, Mita H, Fukutomi Y, Higashi N, Miyazaki E, Kumamoto T, Akiyama K (2009) Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy 39:72-0 CrossRef
7. Abd El-Motaleb GS, Abou Amer AA, Elawa GM, Abo Alsood Abd Elfattah M (2014) Study of urinary leukotriene E4 levels in children with acute asthma. Int J Gen Med 7:131-35 CrossRef
8. González-Nú?ez D, Claria J, Rivera F, Poch E (2001) Increased levels of 12( / S)-HETE in patients with essential hypertension. Hypertension 37:334-38 CrossRef
9. Olson MT, Kickler TS, Lawson JA, McLean RC, Jani J, FitzGerald GA, Rade JJ (2012) Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. J Thromb Haemost 10:2462-469 CrossRef
10. Kim KM, Jung BH, Paeng KJ, Kim I, Chung BC (2004) Increased urinary F(2)-isoprostanes levels in the patients with Alzheimer’s disease. Brain Res Bull 64:47-1 CrossRef
11. Ohnishi H, Saito Y (2013) Eicosapentaenoic acid (EPA) reduces cardiovascular events: relationship with the EPA/arachidonic acid ratio. J Atheroscler Thromb 20:861-77 CrossRef
12. Sublette ME, Galfalvy HC, Hibbeln JR, Keilp JG, Malone KM, Oquendo MA, Mann JJ (2014) Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder. Int J Neuropsychopharmacol 17:383-91 CrossRef
13. Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, Giovannucci EL (2004) Dietary intake of / n-3 and / n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 80:204-16
14. Bannenberg G, Serhan CN (2010) Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta 1801:1260-273 CrossRef
15. Serhan CN (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25:101-37 CrossRef
16. Serhan CN (2010) Novel lipid mediators and - 刊物类别：Chemistry and Materials Science
- 刊物主题：Chemistry
Analytical Chemistry
Food Science
Inorganic Chemistry
Physical Chemistry
Monitoring, Environmental Analysis and Environmental Ecotoxicology - 出版者：Springer Berlin / Heidelberg
- ISSN：1618-2650
文摘
The ω-6 and ω-3 polyunsaturated fatty acids (PUFAs) such as arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) are the precursors of various bioactive lipid mediators including prostaglandins, thromboxanes, leukotrienes, hydroxyeicosatetraenoic acid, isoprostanes, lipoxins, and resolvins (Rvs). These lipid mediators play important roles in various physiological and pathological processes. The quantitative determination of PUFA metabolites seems necessary for disease research and for developing biomarkers. However, there is a paucity of analytical methods for the quantification of ω-6 and ω-3 PUFA metabolites—the specialized pro-resolving mediators (SPMs) present in the human urine. We developed a method for the quantification of ω-6 and ω-3 PUFA metabolites present in human urine using ultra-performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS). The developed method shows good linearity, with a correlation coefficient >0.99 for all of the analytes. The validation results indicate that our method is adequately reliable, accurate, and precise. The method was successfully used to examine urine samples obtained from 43 healthy volunteers. We could identify 20 PUFA metabolites, and this is the first report of the quantitative determination of RvD1, 17(R)-RvD1, 11-dehydro thromboxane B3, RvE2, and 5(S)-HETE in human urine. The urinary 8-iso PGF2α and PGE2 levels were significantly higher in the men smokers than in the men nonsmokers (p--.05). In this study, we developed an accurate, precise, and novel analytical method for estimating the ω-6 and ω-3 PUFA metabolites, and this is the first report that the SPMs derived from EPA and DHA are present in human urine.